Press Release Feb 26 2021
Filed with NSE · · 2 pages · English
Summary by 6ix AI
NATCO Pharma Limited has issued a press release announcing the launch of Brivaracetam tablets in India for the treatment of epilepsy. The tablets will be marketed under the brand name BRECITA and will be available in two strengths at lower prices compared to existing options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from NATCO Pharma
- NATCO Pharma receives approval for Chlorantraniliprole 1st key product of Crop Health Sciences Division
- Press Release Feb 05 2021
- NATCO Pharma launches anti blood clot tablet Rivaroxaban in India
- Press Release Dec 17 2020
- NATCO Pharma receives Pomalidomide approval for US market
Later from NATCO Pharma
- NATCO Pharma launches Brivaracetam tablets, in India, for treatment of epilepsy
- Press Release Mar 08 2021
- Press Release Mar 15 2021
- NATCO Pharma forays into Pheromone based technology for Integrated Pest Management
- Press Release Apr 10 2021
Follow NATCO Pharma into a list and get an email when it puts out news.
Follow NATCO Pharma